Phaseline

Companies › Spark Therapeutics

Spark Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Ophthalmology, Metabolic and endocrine; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Voretigene Neparvovec
Retinoid isomerohydrolase exogenous gene
RPE65Phase 3Inherited Retinal Dystrophy Due to RPE65 Mutations; Leber Congenital AmaurosisOct 2027
SPK-3006
AAV-mediated gene transfer expressing acid alpha-glucosidase (GAA)
GAAPhase 1Pompe DiseaseApr 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01208389Voretigene NeparvovecPhase 1Leber Congenital AmaurosisOphthalmologyOct 2027
NCT00999609Voretigene NeparvovecPhase 3Inherited Retinal Dystrophy Due to RPE65 MutationsOphthalmologyJan 2030
NCT04093349SPK-3006Phase 1Pompe DiseaseMetabolic and endocrineApr 2032

Targets

RPE65 (1) GAA (1)

Companies with the same targets

Innostellar Biotherapeutics Frontera Therapeutics Astellas GeneCradle Amicus Therapeutics Sanofi AskBio

Companies built like this

Innostellar Biotherapeutics GenSight Biologics GeneCradle Orchard Therapeutics Shanghai Vitalgen BioPharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.